Reuters logo
BRIEF-Kura Oncology presents preclinical data on cancer drug
December 1, 2016 / 12:55 PM / 10 months ago

BRIEF-Kura Oncology presents preclinical data on cancer drug

Dec 1 (Reuters) - Kura Oncology Inc:

* Kura Oncology -presented preclinical data highlighting identification, characterization of ko-947, its development candidate targeting erk1/2 kinases

* Kura Oncology - anticipate nominating development candidate for menin-MLL program by 2016 end, initiating phase 1 clinical trial for ko-947 in h1 2017

* Kura Oncology - results from screening large panel of pdx models show that ko-947 induces tumor regressions in braf or ras mutated tumor models

* Kura Oncology - data suggest drug properties of ko-947 may allow Kura to maximize therapeutic window with flexible administration routes and schedules Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below